Claris Biotherapeutics, Inc.
Clinical trials sponsored by Claris Biotherapeutics, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye drop aims to erase corneal scars in early trial Results expected Jun 2027 (estimated)
-
New eye drops aim to repair cornea damage in rare vision disorder
Disease control Recruiting nowThis early-stage trial is testing an experimental eye drop called CSB-001 in 75 people with limbal stem cell deficiency, a condition where the eye's surface can't heal properly, leading to pain and vision loss. The study will check if the drops are safe and if they help improve s…
Phase 1 • Sponsor: Claris Biotherapeutics, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New eye drop aims to erase corneal scars in early trial
Disease control Recruiting nowThis early study tests an experimental eye drop (CSB-001) in 20 people with recent corneal scars (from injury within the last 30 days). Participants use the drops 3-4 times daily for up to 14 days. The main goals are to check safety and see if the drops reduce scar size and impro…
Phase 1 • Sponsor: Claris Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
500-Patient study aims to map rare eye Disease's natural course
Knowledge-focused Recruiting nowThis study watches 500 people with limbal stem cell deficiency (LSCD) to see how the disease changes over time. Researchers will track vision, eye comfort, and physical eye changes using questionnaires and tests. No new treatments are given—the goal is simply to learn more about …
Sponsor: Claris Biotherapeutics, Inc. • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC